Takeda (http://www.takeda.com) is one of the oldest Pharmaceutical companies in the world and has been the largest Japanese Pharmaceutical company for over a decade. Although many of its operations such as development and marketing have been conducted on a global basis for a number of years, research has historically been focused on in-house activities inside Japan, which have a successful track record in generating pioneer blockbuster drugs. To meet the ever-increasing challenge of maintaining a robust pipeline and a continuous stream of INDs, Takeda has embarked on a program to globalize its internal drug discovery capability through the integration of world-class research entities. We outline the strategies, opportunities and challenges of building a global research network from the perspective of a Japanese Pharmaceutical company.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.drudis.2009.03.010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The association of agricultural and non-agricultural work on the healthy ageing of older adults in Japan: A 6-year longitudinal study from the Japan Gerontological evaluation study.
Prev Med Rep
January 2025
Department of Community Building for Well-being, Center for Preventive Medical Sciences, Chiba University, Chiba-shi, Chiba, Japan.
Objectives: Many studies have examined the impact of employment on health, but few large-scale longitudinal studies specifically investigate the impact of agricultural labor on the health of older adults. This study aims to identify the health effects of employment on older Japanese adults, focusing on agricultural workers.
Methods: This study uses longitudinal data collected by the Japan Gerontological Evaluation Study (JAGES) from 2013 to 2019.
Corticosteroid therapy and long-term outcomes in patients with cardiac sarcoidosis stratified by left ventricular ejection fraction.
Eur Heart J Open
January 2025
Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, 2-2 Yamada-oka, Osaka 565-0871, Japan.
Aims: This study aimed to investigate the relationship between corticosteroid therapy and long-term outcomes in patients with cardiac sarcoidosis, stratified by left ventricular ejection fraction (LVEF) at diagnosis.
Methods And Results: This study conducted a analysis of the ILLUstration of the Management and prognosIs of JapaNese PATiEnts with Cardiac Sarcoidosis, a retrospective multicentre registry. Cardiac sarcoidosis was diagnosed based on the 2016 Japanese Circulation Society and 2014 Heart Rhythm Society criteria.
Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: post hoc analysis of the Japanese subpopulation of the TULIP-2 study.
Mod Rheumatol
January 2025
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Objectives: To investigate the efficacy of anifrolumab on disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus (SLE).
Methods: We analysed disease activity and glucocorticoid tapering in the Japanese subpopulation (anifrolumab, n = 24; placebo, n = 19) of the TULIP-2 trial, which showed the efficacy and safety of anifrolumab in patients with moderate-to-severe active SLE.
Results: The percentage of patients who achieved a British Isles Lupus Assessment Group-based Composite Lupus Assessment response at Week 52 was greater in the anifrolumab group than placebo [50.
Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti-cancer agents.
ESC Heart Fail
January 2025
Division of Pharmacotherapeutics, Department of Clinical Pharmacy, School of Pharmacy, Showa University, Tokyo, Japan.
Background: The optimal strategy for modern chemotherapy should be based on a comprehensive approach for cancer patients with cardiovascular diseases. Therefore, cardio-oncology has received increasing attention owing to the cardiotoxic effects of anti-cancer therapies.
Objectives: We aimed to evaluate the clinical characteristics and outcomes of patients with heart failure (HF) who received chemotherapy compared with those of a matched cohort with HF who did not receive chemotherapy, using real-world HF data.
Approaches for difficult-to-induce-seizures electroconvulsive therapy cases (DEC): a Japanese expert consensus.
Ann Gen Psychiatry
January 2025
Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.
Background: Seizure threshold increases with age and the frequency of electroconvulsive therapy (ECT). Therefore, therapeutic seizures can be difficult to induce, even at maximum stimulus charge with available ECT devices. Such cases are known as difficult-to-induce-seizures electroconvulsive therapy cases (DECs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!